Elanco introduces NUPLURA PH+ for cattle
March 10, 2021 - Elanco Animal Health Incorporated has launched a new product that it says brings the cattle industry powerful new options for fast, smooth and flexible protection against bovine respiratory disease (BRD)—one of the deadliest diseases affecting U.S. cattle.
New NUPLURA PH+ builds on the proven performance of NUPLURA PH against Mannheimia haemolytica, while adding protection against common viral causes of BRD, including BVD Types 1 and 2 and IBR.
NUPLURA PH+ provides protective immunity against M. haemolytica in as little as 10 days, which is the fastest immunity claim on the market. M. haemolytica is the primary bacterial cause of pneumonia in cattle. NUPLURA PH+ protects against M. haemolytica and other causes of BRD in calves, as well as in animals at risk for BRD during weaning, branding, shipping, commingling and other times of elevated stress.
For cattle producers concerned about both bacterial and viral causes of BRD, these NUPLURA PH+ options provide additional protection:
NUPLURA PH+BVD delivers additional protection against BVD Types 1 and 2
NUPLURA PH+3 adds protection against BVD Types 1 and 2, plus IBR
“With NUPLURA PH+, the fastest BRD vaccine on the market just got better. Producers can now target bacterial and viral BRD pathogens with one vaccination. This means less stress on the animal, less labor and less time to administer,” said Dr. Brett Terhaar, Elanco Animal Health technical consultant. “Producers have the flexibility to deliver the right protection their herds need, at the right time.”
In addition, NUPLURA PH+ is gentle and safe to use on animals as young as 28 days. Field trials show that calves vaccinated with NUPLURA PH+ stay on feed and water with minimal sweats or other setbacks. With few post-vaccination reactions to overcome, animals can devote energy to growth and productivity.
NUPLURA PH+ is the only M. haemolytica vaccine portfolio that combines recombinant leukotoxoid technology and purified outer membrane proteins (OMPs). These two virulence factors are key to the vaccine’s strong, smooth response.
Using recombinant technology to produce NUPLURA PH+ results in consistently high levels of pure leukotoxoid, which stimulates production of antibodies that bind and inhibit M. haemolytica leukotoxin and allow for a strong immune response. NUPLURA PH+ contains OMPs and is designed for minimal adverse reactions.